Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Ejhaem|June 26, 2026
Salvage With Revumenib: Targeting KMT2A-Rearranged Isolated Leukemia Cutis Identified in the Extramedullary DiseaseBana Antonios, Xuemei Wu, Lynn Johnson, et al.
Leukemia & Lymphoma|February 23, 2024
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerationsNaveen Pemmaraju, Yazan F Madanat, David Rizzieri, et al.
Cancer Medicine|August 19, 2014
Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemiaSanthosh K Sadashiv, Christie Hilton, Cyrus Khan, et al.
Cureus|May 31, 2022
Predictors and Long-Term Outcomes for Diffuse Large B-Cell Lymphoma (DLBCL) Patients Undergoing Surgery Prior to Systemic Therapy: A Nationwide AnalysisUrwat Vusqa, Thejus T Jayakrishnan, Veli Bakalov, et al.
BMC Cancer|February 29, 2016
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark surveyRuben Mesa, Carole B Miller, Maureen Thyne, et al.
Leukemia & Lymphoma|May 21, 2020
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemiaEunice S Wang, Richard Aplenc, Deborah Chirnomas, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 2, 2025
Pregnancy-Related Adverse Events with Tyrosine Kinase Inhibitor Use in Chronic Myeloid Leukemia: A FAERS Pharmacovigilance Analysis (2001-2024)Muhammad Salman Faisal, Aqeeb Ur Rehman, Aleenah Mohsin, et al.
Cancer|October 1, 2016
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark surveyRuben A Mesa, Carole B Miller, Maureen Thyne, et al.
Blood|March 12, 2020
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trialMadan Jagasia, Miguel-Angel Perales, Mark A Schroeder, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Pageof 4